Veterinary Vaccines: Why the Immunological Dossier Needs Its Own Strategy

A vaccine is not a pharmaceutical with an antigen instead of a chemical. Its quality, safety and efficacy evidence, the way it is released and the way it can be used in the field are all shaped by the fact that it is a biological medicine acting on the immune system.

The dossier framework

The technical requirements for veterinary applications are set in Annex II of Regulation (EU) 2019/6, as supplemented by Commission Delegated Regulation (EU) 2021/805. Immunological products have their own requirements within that structure, and they are read together with relevant European Pharmacopoeia texts and VICH guidance.

Where vaccine dossiers differ

  • Quality. Seed lot systems, master and working seeds, antigen characterisation, potency testing and batch consistency carry a heavier weight than in chemical products. A vaccine antigen master file can allow an antigen to be certified once and reused across products.
  • Safety. Beyond target animal safety, live vaccines call for attention to shedding, spread to non-target animals and the possibility of reversion to virulence.
  • Efficacy. Laboratory challenge studies and field trials must show protection or the claimed immunological effect, and the duration of immunity is a typical point of scrutiny.
  • Interference. Use with other vaccines or medicines, and the interpretation of serological tests in vaccinated populations, may need to be addressed.

Batch release and surveillance

Immunologicals face official batch controls before release in the Union, and the holder must keep strong pharmacovigilance for events such as lack of efficacy. Vaccination failures can have consequences for disease control, so they deserve careful investigation.

Disease control and national policy

The Regulation recognises that immunological products interact with animal disease programmes. Under defined circumstances, Member States may restrict the use of such products on their territory, for example where it would conflict with a national control or eradication scheme. Market planning should therefore consider the animal health situation in each country, and not only the authorisation status.

Planning advice

  • Decide early whether any antigen can be covered by a master file.
  • Align the efficacy design with the claims you want on the label.
  • Check how diagnostic testing will interact with your vaccine.
  • Include the batch release step in the launch timeline.

Aligning the plan with development and launch

Because biological products are sensitive to process changes, a late alteration to the manufacturing route can have a significant effect on the data package. Freeze the critical aspects of the process early, plan comparability work for unavoidable changes and keep the clinical and quality teams aligned on what the label will claim. A well-built timeline also includes the time for official batch controls and the lead time for stability data supporting the shelf life.

  • Define the target label claims before designing efficacy studies.
  • Include official batch controls in the supply plan.
  • Track changes to circulating strains that could affect the antigen.

How PQRA helps

PQRA can review your immunological dossier plan against the Annex II and Delegated Regulation structure, identify gaps in the quality, safety and efficacy sections and plan submission and post-authorisation steps around national requirements.

Questions about this topic? Contact PQRA to discuss your veterinary portfolio.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *